Evotec (NASDAQ:EVO) Reaches New 12-Month Low at $5.10

Evotec SE (NASDAQ:EVO)’s stock price reached a new 52-week low on Wednesday . The stock traded as low as $5.10 and last traded at $5.18, with a volume of 512534 shares trading hands. The stock had previously closed at $7.65.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised Evotec from a “hold” rating to a “buy” rating in a research note on Friday, April 12th. Royal Bank of Canada raised shares of Evotec from a “sector perform” rating to an “outperform” rating in a research report on Thursday, January 18th.

Evotec Trading Down 31.4 %

The company’s 50-day moving average price is $7.37 and its 200-day moving average price is $8.71.

Institutional Investors Weigh In On Evotec

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EVO. Quadrant Capital Group LLC acquired a new position in Evotec during the fourth quarter worth approximately $25,000. Optiver Holding B.V. lifted its position in shares of Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after buying an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC bought a new position in shares of Evotec during the 4th quarter worth approximately $53,931,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.